Global Fabry Disease Treatment Market Review 2017-2019 & Forecast to 2025 - Focus on Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy, and Organ-specific Treatment

7/17/2019, 3:25 PM (Source: GlobeNewswire)

Dublin, July 17, 2019 (GLOBE NEWSWIRE) -- The "Fabry Disease Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025" report has been added to's offering.

The report predicts the global fabry disease treatment market to grow with a healthy CAGR over the forecast period from 2019-2025.

The report on the global fabry disease treatment market provides qualitative and quantitative analysis for the period from 2017 to 2025. The study on fabry disease treatment market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on fabry disease treatment market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global fabry disease treatment market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global fabry disease treatment market over the period of 2017 to 2025. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

  • Growing incidences of genetic disorders and increasing awareness

2) Restraints

  • High cost associated with the enzyme replacement therapy

3) Opportunities

  • Increasing number of clinical trials

What does this report deliver?

1. Comprehensive analysis of the global as well as regional markets of the fabry disease treatment market.
2. Complete coverage of all the segments in the fabry disease treatment market to analyze the trends, developments in the global market and forecast of market size up to 2025.
3. Comprehensive analysis of the companies operating in the global fabry disease treatment market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

Key Topics Covered

1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches

2. Executive Summary
2.1. Fabry Disease Treatment Market Highlights
2.2. Fabry Disease Treatment Market Projection
2.3. Fabry Disease Treatment Market Regional Highlights

3. Global Fabry Disease Treatment Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. Growth Matrix Analysis
3.4.1. Growth Matrix Analysis by Treatment Type
3.4.2. Growth Matrix Analysis by Region
3.5. Value Chain Analysis of Fabry Disease Treatment Market

4. Fabry Disease Treatment Market Macro Indicator Analysis

5. Global Fabry Disease Treatment Market by Treatment Type
5.1. Enzyme Replacement Therapy
5.2. Chaperone Treatment
5.3. Substrate Reduction Therapy
5.4. Organ-specific Treatment

6. Global Fabry Disease Treatment Market by Region
6.1. North America
6.2. Europe
6.3. Asia-Pacific
6.4. RoW

7. Company Profiles and Competitive Landscape
7.1. Competitive Landscape in the Global Fabry Disease Treatment Market
7.2. Companies Profiled
7.2.1. Sanofi S.A.
7.2.2. Shire PLC
7.2.3. Amicus Therapeutics Inc.
7.2.4. JCR Pharmaceuticals Co. Ltd.
7.2.5. Avrobio Inc.
7.2.6. ISU Abxis Co. Ltd.
7.2.7. Idorsia Pharmaceuticals Ltd.
7.2.8. Protalix Biotherapeutics Inc.
7.2.9. Moderna Therapeutics Inc.
7.2.10. Greenovation Biotech GmbH

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

         Laura Wood, Senior Press Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs

Primary Logo

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.